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Objective: To describe the current status of breast, colorectal and cervical cancer screening in Spain.
Methodology: The situation was analysed on the basis of data drawn from surveys conducted in each autonomous
region (Comunidad Auto´noma).
Results: Currently, breast cancer screening coverage is 100%. In 2007, overall participation was 67.0% with an
adherence of 91.2%. The detection rate was 3.4&, 15.1% intraductal and 30% invasive <1 cm in diameter, with 65%
showing axilary node negative. Colorectal cancer screening had been implemented in six regions (4.5% of the target
population). Participation ranged from 17.2% to 42.3%, with positive test percentages ranging from 1.7& (guaiac) to
9.5% (immunological). The invasive cancer detection rate was 1.7& (guaiac) and 3.4& (immunological). In most
cases, cervical cancer screening was undertaken opportunistically, with an estimated coverage of 69.0%.
Conclusions: In Spain, cancer screening is being conducted in accordance with national and international
recommendations. The fact that screening programmes are operated as a network has led to a high degree of
consensus as to the methodology and information systems to be used to enable joint evaluation.
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introduction
Cancer constitutes one of the major health problems in the
developed world. In absolute terms, it is the leading cause of
mortality in Spain, accounting for >25% of all deaths. The most
frequent tumour sites are as follows: among men, lung, colon
and rectum, and prostate [1, 2]; and among women, breast
followed by colon and rectum. Cervical cancer accounts for
only 3% of all tumours diagnosed.
As a secondary prevention activity, screening is a method
that has shown itself to be effective in improving prognosis of
a relevant number of patients in certain types of cancer. As far
back as 2003, the European Union recommended that
population-based breast, cervical and colorectal cancer
screening be undertaken [3], and established the basic action
criteria to guarantee quality and results in health terms. Since
then, practically all European countries have implemented
screening programmes, albeit with different organisational
models [4]. In Spain, the 2009 National Health System (NHS)
Cancer Strategy also recommends that such screening be
conducted and lays down the minimum criteria for its
implementation and development [5].
The organisation of Spain’s NHS is decentralised, with
responsibility being delegated to the regional health systems of
the country’s 17 autonomous regions (ARs) (Comunidades
Auto´nomas) and the autonomous cities (Ciudades Auto´nomas)
of Ceuta and Melilla [6], each of which is responsible for local
application of these programmes. This type of territorial
organisation, with widely decentralised powers, has led to
differing application of cancer screening policies in the various
ARs. Nevertheless, 20 years ago, coinciding with the
commencement in Spain of the first breast cancer screening
programmes, a network was set up. This is the ‘Network of
Spanish Cancer Screening Programmes’ (Red de Programas
Espan˜oles de Cribado de Ca´ncer) (initially covering breast
cancer), which, in addition to sharing information and
experience in this field, has allowed for inter-regional
co-ordination aimed at reaching agreement on the basic criteria
for implementation and development of the respective
screening programmes, as well as defining the indicators that
would, as far as possible, enable joint evaluation [7]. One
example of this type of evaluation is the ‘DESCRIC Report’ [8],
drawn up in 2006 for the purpose of describing at that time the
status of screening in Spain and updating the pertinent
scientific evidence.
This article describes the current status of implementation of
the different screening programmes in Spain in respect of the
three cancers for which screening is clearly recommended,
namely, breast, colorectal and cervical, and the differences
arising from the Spanish health system’s decentralised
organisation. Coverage indicators and, as far as possible, the
results of the activities undertaken are analysed for each type of
cancer.
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subjects and methods
The organisation and development of the respective screening programmes
is independent. Consequently, the methodology used for data collection
and analysis was different for each tumour type, although the health
structure of the ARs means that in many cases these come under the same
departments and the same heath officials and managers.
breast cancer
The data shown here were drawn from the annual survey conducted by the
Network of Spanish Cancer Screening Programmes for the purpose of
updating information on the characteristics of each programme.
Simultaneously, data on annual activity were collected in a structured
manner so as to assess these programmes overall. This study analysed data
for 2007, the last year for which final information was available.
Indicators were calculated as per the definitions laid down in the
European Guidelines for Quality Assurance in Breast Cancer Screening and
Diagnosis [9]. The results obtained were compared with the reference values
established in the above-mentioned guidelines.
A total of 16 of the 19 ARs responded to the questionnaire, so that we
had information corresponding to almost 90% of the activity undertaken
(Table 1). In the case of one AR, there were no data on the age of the
women examined (21 899 examinations, 1.7% of the total). Data broken
down by type of examination were obtained for nine ARs, which accounted
for 60% of the examinations (75% of initial examinations).
colorectal cancer
With respect to colorectal cancer screening, these programmes form part of
the Network of Spanish Cancer Screening Programmes. Applying similar
criteria to those described above, a first questionnaire was drawn up which
gathered data on programme characteristics, i.e. year of introduction, target
population, methodology, quality-control systems, etc. We agreed on
assessment indicators, such as participation, positive test, invasive cancer
and neoplastic lesion detection rates, and rate of advanced cancers, which
would be analysed jointly for all programmes, in line with the criteria
stipulated by the European Cancer Network group of experts in the quality
guideline currently being drawn up.
This study describes the current status of this type of screening and
analyses the data on the results of programmes that had concluded
a minimum of a first round.
cervical cancer
Almost all cervical cancer screening activity is undertaken opportunistically.
Data on the status of the programmes and a description of the criteria upon
which this activity is implemented were obtained by means of
a questionnaire sent to the heath officials and managers of each AR [8]. To
ascertain coverage, including both public and private health systems, data
from two surveys were analysed. These were the 2006 National Health
Survey (Encuesta Nacional de Salud) [10] and a study which in 2005
evaluated practice and factors linked to cervical cancer screening in Spain,
based on a survey of 6852 women aged 18–70 years drawn from 17 ARs
(AFRODITA Study) [11].
results
breast cancer screening
Currently, Spain’s 17 ARs and 2 autonomous cities all have
population-based breast cancer screening programmes. Navarre
was the first to implement its programme, with this being
Table 1. Women invited and explored by breast cancer screening programmes in 2007 (age range 45–69 years)
Autonomous region Women
invited
Women
explored
Women
explored by
age group
Women
explored
by type of
exploration
Initial
screening
Subsequent
regular
screeninga
Andalusiab 319 721 244 388 244 388 244 388 49 772 182 054
Aragon 52 425 35 410 35 410 35 410 7929 26 646
Prinicpality of Asturias 54 561 41 860 41 860 NA NA NA
Balearic Isles 33 992 26 099 26 099 26 099 4580 11 860
Canary Islands NA NA NA NA NA NA
Cantabria 32 540 21 899 NA NA NA NA
Castile–La Mancha 121 036 77 076 77 076 77 076 13 130 59 389
Castile–Leo´n NA NA NA NA NA NA
Catalonia 341 045 220 022 220 022 NA 42 897 NA
Valencian region 243 546 176 954 176 954 176 954 28 819 142 775
Extremadura 55 900 37 751 37 751 NA NA NA
Galicia 136 564 106 387 106 387 106 387 15 778 83 266
Madrid (region) 301 227 119 778 119 778 NA NA NA
Murcia (region) 60 798 43 425 43 425 43 425 7447 34 455
Navarre 44 084 38 031 38 031 38 031 3761 33 669
Basque Country 116 228 88 444 88 444 NA NA NA
La Rioja 16 759 15 525 15 525 15 525 2058 12 842
Autonomous City of Ceuta 651 569 569 NA NA NA
Autonomous City of Melilla NA NA NA NA NA NA
Total 1 931 077 1 293 618 1 271 719 763 295 176 171 586 956
a£2.5 years since previous screening.
bData corresponding to 80% of the autonomous region.
NA, not available.
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initiated in 1990, and was progressively followed by the
remaining ARs. All these programmes have already attained
100% coverage.
For each region Table 1 describes the number of women
invited along with some relevant results. All the programmes
included women aged 50–64 years in their target population:
three started at age 45 years and, though they all began by
having an upper age limit of 65 years, at the time of writing all
had raised or were in the process of raising this to age 69 years
(Table 2). In general, all women were personally invited every
2 years. In all cases, two mammographic projections were made
during both the initial and—except in one
programme—successive rounds. The classification used for
mammogram reading was the Bi-Rads (or compatible)
classification, and all regions used the physical quality control
protocols established in the European Guidelines.
participation. Mean overall participation was 67.0%. On the
whole, analysis by age group displayed no significant
differences, though the trend was upward. Participation of
women invited to the programmes for the first time was 63.8%,
and showed a clear downward trend with age (Table 3).
Insofar as programme adherence was concerned, 91.2%
(86%–97% depending on the AR) of all women who
participated in the previous round, took part in the current
round, thus indicating the acceptability of the programmes
once a woman has joined them. As in the case of participation,
there were no significant differences by age group.
cancer detection rates and characteristics of diagnosed
tumours. The overall detection rate was 3.4& of explored
women, showing a growing trend with age for both initial and
subsequent examinations, with the rate in all cases being higher
in the first group.
With respect to type of tumour diagnosed, no data could be
obtained in 12% of cases. Of the remainder, 15.1% were
intraductal, with a slight difference between the two subgroups
of women analysed. Almost 30% of invasive cancers were
a maximum of 1 cm in diameter. A significantly lower
percentage was observed among the initial group of women
(20.8%) compared with successive groups (28.9%), though in
both cases these percentages were close to the desirable
reference values of 25% and 30%, respectively. In all, only
22.4% of invasive tumours exceeded 2 cm in diameter. In this
case, the difference between women who were examined for the
first time and those who had been previously examined was not
quite as marked.
A little over 65% of tumours detected showed no ganglion
infiltration. No difference was observed according to type of
examination performed.
colorectal cancer screening
In line with European Council and NHS Cancer Strategy
recommendations, as a target of their health and/or oncological
health plans Spain’s ARs have been incorporating
a commitment to conducting pilot studies for the
implementation of population-based screening programmes
and the development of strategies for care of high-risk
individuals and families. Related scientific societies have made
recommendations and drawn up clinical practice guidelines,
insisting on the need for these types of programme to be
implemented [12].
In 2007, consensus meetings were held to establish the
methodology and information systems on which such
programmes should be based, in order to ensure their quality
and continuity [13].
first-round coverage and results. Of Spain’s 17 ARs, six have
initiated screening programmes, i.e. Catalonia, Valencian
Region, Murcia, Basque Country, Cantabria and the Canary
Islands, representing 40% of the Spanish population (Table 4).
The remainder have undertaken to initiate this activity
progressively in the short term.
The programmes currently in operation include men and
women aged 50–69 years as their target population (except
Cantabria which starts at age 55 years). In 2009, 418 973
persons were included in a screening programme (4.5% of the
Spanish population in this age group, 9500 000 persons), and
by 2014 minimum coverage is estimated to be 50%.
The test used was the faecal occult blood est (FOBT), based
on guaiac resin in the first round in Catalonia and Valencia,
and on immunoassay in Murcia and the Basque Country. In
subsequent rounds, the immunological test was also
incorporated into the Catalonian and Valencian programmes.
As far as periodicity was concerned, in all cases tests were
repeated every 2 years.
The first-round results of pilot studies in four regions were
available (Catalonia since 2000 [14], Valencia 2005, Murcia
2006 and the Basque Country 2008) (Table 5). Participation
ranged from 17.2% to 59.0% (Catalonia attained a second-
round figure of 22%).
Table 2. Characteristics of Spanish breast cancer screening programmes
Autonomous
region
Year
programme
started
Year
100%
coverage
Age
group
Women
invited
2007 (n)
Andalusia 1995 2005 45–69 319 721a
Aragon 1997 2006 50–69 52 425
Prinicpality of Asturias 1991 2000 50–69 54 561
Balearic Isles 1997 2009 50–69 33 992
Canary Islands 1999 2005 50–69 NA
Cantabria 1997 1997 50–69 32 540
Castile–La Mancha 1992 1997 45–69 121 036
Castile–Leo´n 1992 1996 50–69 NA
Catalonia 1992 2004 50–69 341 045
Valencian region 1992 2001 45–69 243 546
Extremadura 1998 2005 50–69 55 900
Galicia 1992 1998 50–69 136 564
Madrid (region) 1999 2001 50–69 301 227
Murcia (region) 1995 1999 50–69 60 798
Navarre 1990 1992 45–69 44 084
Basque Country 1995 2000 50–69 116 228
La Rioja 1993 1995 45–69 16 759
Autonomous City of Ceuta 2001 2006 45–69 651
Autonomous City of Melilla 1997 1997 45–69 NA
Total
aData corresponding to 80% of the autonomous region.
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Table 3. Early indicators of screening efficacy for Spanish programmes overall, according to age group and type of exploration
45–49 50–54 55–59 60–64 65–69 Unknownb
(50–69)
Total 45–69 Total 50–69
Total screeningsa
Women invited (n) 128 405 554 340 471 830 440 535 303 427 32 540 1 931 077 1 802 672
Women explored (n) 85 901 356 735 322 735 309 985 196 363 21 899 1 293 618 1 207 717
Participation rate (%) 66.9 64.4 68.4 70.4 64.7 67.3 67.0 67.0
Breast cancers detected (n) 263 1010 931 1243 848 78 4373 4110
Breast cancer detection rate
(per 1000 women)
3.1 2.8 2.9 4.0 4.3 3.6 3.4 3.4
DCIS (%) 12.9 15.7 13.7 11.5 12.1 19.2 13.3 13.3
Invasive (%) 83.3 71.0 73.3 75.1 77.6 73.1 74.7 74.1
Unknown/not available (%) 3.8 13.3 13.0 13.4 10.3 7.7 12.0 12.5
DCIS in cancers with
data available (%)
13.4 18.2 15.8 13.3 13.5 20.8 15.1 15.2
Invasive cancers £10 mm/total
cancers (%)
15.6 20.0 21.2 21.3 23.8 34.6 21.4 21.7
Invasive cancers £10 mm/total
invasive cancers (%)
18.7 28.2 28.9 28.4 30.7 47.4 28.6 29.3
Invasive cancers £10 mm/1000
explored women (%)
0.5 0.6 0.6 0.9 1.0 1.2 0.7 0.7
Invasive cancers >20 mm/total
invasive cancers (%)
31.1 21.9 23.8 21.0 21.1 19.3 22.4 21.8
Invasive cancers >20 mm/1000
explored women (%)
0.8 0.4 0.5 0.6 0.7 0.5 0.6 0.6
Node-negative invasive
cancers/total invasive
cancers (%)
59.8 62.8 66.7 68.5 69.1 82.5 66.7 67.1
Node-negative cancers/total
cancers (%)
62.7 60.3 62.6 62.9 65.8 79.5 63.1 63.1
Initial screeningc
Women invited (n) 77 407 193 515 67 215 55 527 39 949 433 613 356 206
Women explored (n) 40 608 97 549 17 820 12 800 7394 176 171 135 563
Participation rate (%) 52.4 50.4 26.5 23.1 18.5 40.6 38.1
Women invited 1st
invitation (n)
57 197 68 481 9379 6417 4814 146 288 89 091
Women explored 1st
invitation (n)
34 978 45 648 5895 4027 2809 93 357 58 379
Participation rate 1st
invitation (%)
61.2 66.7 62.9 62.8 58.4 63.8 65.5
Breast cancers detected (n) 150 324 80 115 57 726 576
Breast cancer detection rate
(per 1000 women)
3.7 3.3 4.5 9.0 7.7 4.1 4.2
DCIS (%) 12.0 18.2 10.0 7.0 8.8 13.5 13.9
Invasive (%) 85.3 60.8 70.0 79.1 82.5 71.5 67.9
Unknown/not available (%) 2.7 21.0 20.0 13.9 8.8 15.0 18.2
DCIS in cancers with data
available (%)
12.3 23.0 12.5 8.1 9.6 15.9 17.0
Invasive cancers £10 mm/total
cancers (%)
14.7 16.7 11.3 8.7 22.8 14.9 14.9
Invasive cancers £10 mm/total
invasive cancers (%)
17.2 27.4 16.1 11.0 27.7 20.8 22.0
Invasive cancers £10 mm/1000
explored women (%)
0.5 0.6 0.5 0.8 1.8 0.6 0.6
Invasive cancers >20 mm/total
invasive cancers (%)
30.5 27.4 21.4 19.8 23.4 25.8 24.3
Invasive cancers >20 mm/1000
explored women (%)
1.0 0.6 0.7 1.4 1.5 0.8 0.7
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The positive test percentage ranged from 1.7% to 9.5%, with
an invasive cancer detection rate of 1.7& to 3.4&.
cervical cancer screening
In Spain, all ARs currently had cervical cancer screening
programmes (Table 6), though these were mostly of the
opportunistic type, except in La Rioja where the programme
was population based (direct invitation by mail) and in Castile
and Leo´n where, despite there being no direct appointment
system, a protocolised awareness-raising campaign was directed
at the target population so that they would seek screening.
Some ARs were debating whether to complete the
opportunistic strategy by implementing pilot projects that
included other capture strategies. The scope of performance of
the test was delimited to primary and specialised care, and
family planning.
Programmes varied in terms of starting age and screening
interval, reflecting the lack of consensus among scientific
societies, though in the NHS Cancer Strategy
a recommendation is made in this regard. There was
a predominance of protocols that included women aged 25–65
years, with a periodicity of 3–5 years.
In terms of technique, the Papanicolau smear (Pap smear)
was used in all ARs, in some cases with liquid-based cytology.
Determination of the papilloma virus was used in some
programmes for specific situations (cytologies of unknown
significance, women with inadequate previous screening or
at-risk populations).
screening coverage. The percentage of women effectively
covered by the screening test in the target population was
relatively high. In the 2006 National Health Survey [9], 69.0%
of women aged >20 years reported having undergone cytology
at least once, with percentages that ranged from 55% to 80%
depending on the AR. In nine of the ARs studied, accounting
for 54.2% of the Spanish population, this percentage ranged
Table 3. (Continued)
45–49 50–54 55–59 60–64 65–69 Unknownb
(50–69)
Total 45–69 Total 50–69
Node-negative invasive
cancers/total invasive
cancers (%)
60.9 64.0 64.3 80.2 53.2 65.1 66.5
Node-negative cancers/
total cancers (%)
64.0 57.1 55.0 70.4 52.6 60.1 59.0
Subsequent screeningsd (£2.5
years since previous screening)
Women invited (n) 48 277 144 254 168 173 163 707 119 145 643 556 595 279
Women explored (n) 43 415 130 997 155 794 152 745 104 005 586 956 543 541
Participaion rate (%) 89.9 90.8 92.6 93.3 87.3 91.2 91.3
Breast cancers detected 107 323 444 616 359 1849 1742
Breast cancer detection
rate (per 1000 women)
2.5 2.5 2.8 4.0 3.5 3.2 3.2
DCIS (%) 15.0 13.6 14.4 12.8 13.7 13.6 13.6
Invasive (%) 81.3 83.0 75.2 75.8 84.1 78.9 78.7
Unknown/not available (%) 3.7 3.4 10.4 11.4 2.2 7.5 7.8
DCIS in cancers with data
available (%)
15.5 14.1 16.1 14.5 14.0 14.7 14.7
Invasive cancers £10 mm/total
cancers (%)
17.8 23.6 21.6 21.4 27.6 22.8 23.1
Invasive cancers £10 mm/total
invasive cancers (%)
21.8 28.4 28.7 28.3 32.8 28.9 29.4
Invasive cancers £10 mm/1000
explored women (%)
0.4 0.6 0.6 0.9 1.0 0.7 0.7
Invasive cancers >20 mm/total
invasive cancerscancers (%)
28.7 20.2 26.1 25.3 16.6 22.9 22.5
Invasive cancers >20 mm/1000
explored women (%)
0.6 0.4 0.6 0.8 0.5 0.6 0.6
Node-negative invasive
cancers/total invasive
cancers (%)
60.9 63.4 65.9 63.0 71.2 65.3 66.6
Node-negative cancers/total
cancers (%)
64.3 66.3 64.0 60.6 73.5 65.1 65.2
aData included from all autonomous regions.
bData correspond to a single autonomous region that includes women aged 50–69 years in its target population.
cData included only from those autonomous regions that broke down the information by type of examination (80% of the total).
DCIS, ductal carcinoma in situ.
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from 60% to 70%. In five of these (37.9% of the total
population), this stood at 70%–80%, with the 80% mark
being surpassed in only one (4.5% of the population). Overall
coverage proved highest in the 45- to 54-year group (86.3%),
and decreased in the younger and older groups (Figure 1). With
respect to the screening interval, most women reported an
annual periodicity in the performance of cytology, across all age
groups (Table 7).
The results of the AFRODITA Study [11] reveal higher
coverage figures. According to this study, 86% of women
reported having undergone cytology at some time in their lives,
42% in the preceding year, 69% in the preceding 3 years and
75% in the preceding 5 years. The data indicated lower
coverages among women who were older, had a low socio-
economic level and came from rural areas. These figures ranged
from 85.9% of women who had undergone at least one cytology
in the preceding 3 years in the Canary Islands to 61.3% in
Extremadura.
discussion
Cancer screening has been proposed as an effective control
method for certain types of cancer and in this respect has been
recommended by numerous scientific organisations and
societies. Europe is a model for implementation of organised
population-based programmes and, in our case, the drawing-
up of European quality guidelines for breast cancer, cervical
and, in the near future, colorectal cancer screening programmes,
has been instrumental in the development of screening
programmes in this country. This fact has been extremely
relevant in discussions held at the screening programme
network and has enabled consensus to be reached on indicators,
quality criteria and assessment of regional programmes. As
a result, one can now speak of a reasonably uniform screening
programme in Spain for breast cancer, and probably for
colorectal cancer as well. Likewise, existing initial differences
have been reduced. Of equal note is the convergence, in terms of
consideration being given exclusively to an opportunistic
cervical cancer screening strategy, which is in evidence in all
regions and is reflected in the NHS Cancer Strategy.
Since 1990, the year in which the first population-based
breast cancer screening programme was implemented in Spain,
the interest and priority devoted to its implementation and
development have, in part, been endorsed by all health
authorities, national and regional. Breast cancer screening
programmes in Spain have already attained 100% coverage.
Special mention should be made of the notable acceptability of
screening mammography as part of organised programmes, as
is shown by the overall participation and high degree of
adherence.
Given the variability in implementation of programmes and
the time elapsed since many of them were started, an accurate
Table 4. Characteristics of Spanish colorectal cancer screening programmes
Autonomous region Catalonia Valencian region Murcia region Basque Country Cantabria Canary Islands
Year of implementation 2000 2005 2006 2008 2008 2009
Age of target
population (years)
50–69 50–69 50–69 50–69 55–69 50–69
Target population (n) 1 541 917 1 080 728 257 778 490 371 93 543 369 027
Target population covered
by programme in
2009, n (%)
84 278 (5.4) 176 562 (16.3) 35 741 (13.8) 28 173 (5.7) 20 219 (21.6) 74 000 (20.0)
Type of invitation Personalised letter Personalised letter Personalised letter Personalised letter Personalised letter Personalised letter
Screening test Guaiac/immunological
FOBT
Guaiac/immunological
FOBT
Immunological
FOBT
Immunological
FOBT
Immunological
FOBT
Immunological
FOBT
Screening interval (years) 2 2 2 2 2 2
FOBT, faecal occult blood test.
Table 5. First-round results of colorectal cancer screening programmes in Spain
Autonomous region Catalonia Valencian region Murcia region Basque Country
Target population
(1st round) (n)
64 866 106 653 35 741 28 187
Population invited 63 880 98 682 35 741 27 245
Population examined
(with valid test)
11 011 34 691 15 101 16 066
Participation rate (%) 17.2 35.2 42.3 59.0
Positive test, n (%) 372 (3.4) 579 (1.7) 1430 (9.5) 1269 (7.9)
Invasive cancers detected (n) 23 59 52 55
Invasive cancer detection
rate per 1000 population
2.1 1.7 3.4 3.4
original article Annals of Oncology
iii48 | Ascunce et al. Volume 21 | Supplement 3 | May 2010
estimate of expected overall incidence in Spain could not be
made but, judging by the partial results, the detection rate can
be estimated to lie within the expected range. The types of
tumour detected are consistent with the diagnostic in advance
that these programmes yield. The various indicators—in the
majority of cases in line with the recommendations established
by the European guidelines and, moreover, similar to those in
other countries [15]—suggest that mortality in Spain will
decline significantly, as is indicated by the fact that this is
already taking place in the regions where these programmes
were originally introduced [16].
The situation with respect to colorectal screening is
somewhat different. Compared with the extent of its
deployment in other European countries, implementation of
this type of screening is extremely limited in Spain [4]. Only six
ARs are developing pilot programmes in the initial stages,
though most of the remainder envisage initiating similar
projects in 1 or 2 years’ time. It is envisaged that colorectal
screening will be extended to at least 50% of the target
population within a period of 5 years. The time of
implementation will enable it to be extended, using the lessons
learnt from the experience of implementing and developing
breast cancer screening programmes. Indeed, the fact that from
the outset a network of existing programmes is in place is a step
in this direction.
The participation obtained in the programmes undertaken in
Spain shows great variability and is below that obtained in
other programmes in Europe, e.g. 56.8% in the UK [17] and
44.6% in Italy [18]. Informing the public as to the importance
of this health problem and the possibilities of prevention and
early diagnosis is crucial to enhancing the effectiveness of such
actions.
Insofar as the percentage of positive tests is concerned, the
differences can be attributed to the test used (guaiac or
immunological), since these same differences are observed in
other European programmes when different tests are also used
[17, 18]. The same can be concluded with regard to the invasive
cancer detection rate.
Table 6. Principal characteristics of cervical cancer screening programmes in Spain
Autonomous region Type of programme Age of target
population (years)
Periodicity Technique used
Andalusiab Opportunistic 20–60 Every 3 years Cytology
Aragon Opportunistic 35–64 After two normal annual
cytologies, follow-up every
3–5 years
Cytology
Prinicpality of Asturias Opportunistic 25–65 After two normal annual
cytologies, follow-up every
3 years
Cytology
Balearic Isles Opportunistic 25–64 Every 3 years Cytology and liquid cytology
Canary Islands Opportunistic 18–65 After two normal annual
cytologies, follow-up every
3 years
Cytology
Cantabria Opportunistic 25–65 After two normal annual
cytologies, follow-up every
5 years
Cytology
Castile–La Mancha Opportunistic 25–60 Every 3 years Cytology and liquid cytology
Castile–Leo´n Scheduled 30–65 After two normal annual
cytologies, follow-up every
3 years
Cytology
Catalonia Opportunistic 25–65 Every 3 years Cytology
Valencian region Opportunistic 20–65 Every 3 years Cytology
Extremadura Opportunistic 20–65 After two normal annual
cytologies, follow-up every
3 years
Cytology and liquid cytology
Galicia Opportunistic 20–65 Every 3 years Cytology and liquid cytology
Madrid (region) Opportunistic 35–65 No periodicity Cytology
Murcia (region) Opportunistic 35–64 After two normal annual
cytologies, follow-up every
5 years
Cytology
Navarre Opportunistic 25–65 From 3 to 5 years Cytology
Basque Country Opportunistic 25–59 After two normal annual
cytologies, follow-up every
3–5 years
Cytology
La Rioja Population based 25–65 Every 3 years Cytology
Modified from the DESCRIC Report.
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The principal argument used for applying cervical cancer
screening with an opportunist strategy is the low frequency of
this tumour in this country. Organised programmes have
shown that both incidence and mortality are reduced: albeit to
a lesser degree, opportunistic programmes also manage to
reduce these rates [19, 20], though this type of strategy may
entail inequalities of access.
The information furnished by cross-sectional studies and
Spanish health surveys indicates that opportunistic screening
coverages are high, though there is a difference of 17 percentage
points between the two sources used [10, 11].
This difference may be linked to the different characteristics
of the respective surveys, since, unlike the AFRODITA study in
which this aspect was investigated to the exclusion of all others,
the fact that many other health-related aspects are included in
the National Health Survey might lead to a lower recall effort in
specific responses on cervical screening. The data suggest,
moreover, that whereas many women undergo cytology more
frequently than is recommended, there are groups of women
among whom coverage must nevertheless be improved (older
women, rural areas and less privileged social levels).
In view of this situation and the absence of population-based
programmes, most of Spain faces the challenge of boosting
opportunistic screening in an attempt to attain the following
two fundamental goals: on the one hand, to improve coverage,
particularly in the above-mentioned subgroups, so as to reduce
inequalities of accessibility; and, on the other, to standardise
criteria, in terms of both starting age and screening interval, so
as to prevent many women from undergoing cytology more
frequently than is recommended. Finally, a specific effort
should be made by health authorities to assure screening test
quality, which, in an opportunistic context, is something that
merits special attention.
In conclusion, cancer screening practice in Spain is being
performed in accordance with the pertinent national and
international recommendations. Despite the decentralisation of
health competencies in the respective regional health systems,
the fact that screening programmes are operated as a network
has led to a high degree of consensus on methodology and
information systems, which in turn allows for joint evaluation
and comparison of results.
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